Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
PYRIPROXYFEN
Virbac S.A.
QP53AX23
PYRIPROXYFEN
30 Milligram
Spot On Solution
POM
Canine
Pyriproxifen
Ectoparasiticide
Authorised
2000-09-15
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Cyclio 30 mg Spot-on Solution for Medium Sized Dogs. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION For one pipette containing 1.5 ml of solution : ACTIVE SUBSTANCE: Pyriproxyfen........................................................ 30 mg EXCIPIENT(S): Butylated hydroxyanisole (E320)........................... 0.270 mg For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Spot-on solution. Clear solution. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Prevention of flea multiplication (adult and larval stages of _Ctenocephalides felis _sensitive to pyriproxyfen) in dogs weighing over 6kg up to 15kg by inhibiting egg development for 3 months. 4.3 CONTRAINDICATIONS Do not use in puppies less than 1 month of age or in sick or convalescing dogs. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES In case several animals are part of the same household, appropriate treatment should be carried out for each animal. As for any parasiticidal product, its frequent and repeated use may cause the development of parasite resistance to the active ingredient. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 28/02/2011_ _CRN 7009971_ _page number: 1_ 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS Infestations occurring during the initial administration or appearing during the treatment period may be eliminated with appropriate medicinal insecticides. The influence of bathing or wetting immediately after treatment has not been evaluated. Therefore the efficacy may be reduced if the animal is wetted or shampooed up to 3 days after the treatment. SPECIAL PRECAUTION Read the complete document